Safety and Efficacy Study of ONGLYZA (Saxagliptin) Under Conditions of Actual Use

AstraZeneca542 enrolled

Overview

This post marketing surveillance study aims to monitor the safety and efficacy of ONGLYZA under conditions of actual use in patients who are diagnosed with diabetes mellitus type 2 and are prescribed ONGLYZA by their physician.

Study Type

OBSERVATIONAL

Enrollment

542

Conditions

Type 2 Diabetes Mellitus

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of Type 2 Diabetes Mellitus * Prescribed Saxagliptin by patient's attending physician Exclusion Criteria: * Known allergic or serious adverse reaction to Saxagliptin * Pregnant or breastfeeding patients

Locations (11)

Research Site

Batangas, Batangas, Philippines

Research Site

Cebu City, Cebu, Philippines

Research Site

Davao City, Davao Region, Philippines

Research Site

Iloilo City, Iloilo, Philippines

Outcomes

Primary Outcomes

Adverse events observed during the treatment duration

Time frame: Upon enrollment and initiation of Saxagliptin up to 14 days post follow-up

Clinical Response determined by cure rate

Time frame: Up to three (3) months after initiation of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.